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Abstract
Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60% of patients receive
salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of
second-line treatment of advanced gastric cancer. MEDLINE/PubMed and Cochrane Library were searched for randomized
phase III trials that compared active therapy to best supportive care in advanced gastric cancer. Data extraction was
conducted according to the PRISMA statement. Summary HR for OS was calculated using a hierarchical Bayesian model and
subgroup analysis was performed based on baseline Eastern Cooperative Oncology Group Performance Status (ECOG)
performance status (0 vs. 1 or more). A total of 1,407 patients were evaluable for efficacy, 908 were treated in the
experimental arms, with chemotherapy (231 pts) or with targeted therapies (677 pts). The risk of death was decreased by
18% (HR = 0.82; 95% CI, 0.79–0.85; posterior probability HR$1: ,0.00001) with active therapies. Chemotherapy and
ramucirumab were able to decrease this risk by 27% and 22%, respectively. No differences were found between
chemotherapy and ramucirumab. In patients with ECOG=0 a greater benefit was found for chemotherapy with a reduction
of the risk of death by 43% and no benefits were found for ramucirumab or everolimus. In patients with ECOG=1 or more a
significant reduction of the risk of death by 32% was reported in patients treated with ramucirumab, even if no significant
difference was reported between chemotherapy and ramucirumab. This analysis reports that active and available therapies
are able to prolong survival in patients with advanced gastric cancer with a different outcome based on initial patient’s
performance status. New trials based on a better patient stratification are awaited.
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Introduction
Gastric cancer (GC) is the third leading cause of cancer death in
both sexes worldwide (8.8% of the total), with the highest
estimated mortality rates in Eastern Asia and the lowest in
Northern America. High mortality rates are also present in both
sexes in Central and Eastern Europe, and in Central and South
America [1].
Systemic chemotherapy is a cornerstone in treatments of GC
both in locally-advanced and metastatic disease. Although no
standard regimen for the first-line chemotherapy have been set up
on a global scale, its use is associated with a consistent reduction of
the risk of death over best supportive care and the combination
chemotherapy with cisplatin and fluoropyrimidine (5-FU) im-
proves survival compared to single-agent 5-FU [2].
Considering the new treatment in first-line therapy options,
whereas trastuzumab with standard fluoropyrimidine/cisplatin
regimen is recommended in patients with HER-2 positive tumors,
two and three-drug regimens including 5-FU, cisplatin, with or
without an antracyclines, as well as irinotecan or docetaxel-
containing regimens are reasonable treatment options for HER-2
negative patients [3,4].
Despite the majority of patients receive first-line therapy, the
analysis of patients enrolled in upfront clinical trials revealed that
the attitude towards second-line chemotherapy differ between
European and Japanese studies, with a percentage of 14% in
REAL-2 and 75% in the SPIRITS study [5,6].
Regarding patients treated in clinical practice, these percentages
are even lower - with only about 45% receiving a salvage
treatment compared to Japanese clinical studies. Despite the low
number of patients treated in the second-line setting and intrinsic
biases, the outcomes of patients receiving a salvage treatment
seemed to be influenced positively, with survival times exceeding
one year [7,8].
In recent years, several studies reported that second-line
chemotherapy is not the only effective strategy able to increase
survival in patients with advanced GC focusing on vascular
endothelial growth factor receptor (VEGFR) as new target. In
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particular, VEGFR-2 is over-expressed in GC tissue as compared
to normal mucosa and in presence of lymph nodal metastases [9].
Recent trials reported such as a monoclonal antibody –
ramucirumab – or a tyrosine kinase inhibitor – apatinib – against
the VEGFR-2 are able to increase the progression free survival
and the overall survival in patients treated with one or two
previous line of therapies [10,11].
The aim of this meta-analysis was to estimate the effect of
second-line treatment of GC and to analyze the differential role of
chemotherapy or targeted agents. We also investigated if different
strategies have the same role in patients with different perfor-
mance status, with the intent to find the best strategy for second-
line treatment of this tumor.
Methods
Definition of the outcome
For each trial, chemotherapy or targeted therapy as single
agents were considered as the experimental treatment and the
placebo or the best supportive care (BSC) as the control one.
Results were reported for the entire cohort and by type of
treatments (chemotherapy, everolimus, ramucirumab), separately.
Selection of the studies
We reviewed MEDLINE/PubMed and Cochrane Library for
citations from January 2004 to February 2014. The search criteria
were limited to articles published in English language and phase
III clinical trials using appropriate filters available on PubMed.
The entry term for the search was ‘‘gastric tumor’’. During the
selection process, search was further restricted to randomized
controlled trials in which chemotherapy agents or targeted agent
were used as second-line of therapy after first-line platinum- and
fluoropyrimidine-based combination therapy over placebo or best
supportive care for treatment of advanced gastric cancer. If more
than one publication was found for the same trial, the most recent
was considered for analysis.
Study quality was assessed by using the Jadad seven-item scale
that included randomization, double blinding and withdrawals;
the final score was reported between 0 and 5 [12].
Data extraction
Data’s extraction was conducted independently by two co-
authors (R.I. and C.M.) according to the Preferred Reporting
Items for Systematic review and Meta-Analysis (PRISMA)
statement (Checklist S1) [13]; any discrepancies were resolved
by consensus between the two authors. The data obtained for each
trial were reported in the presented tables, these were: first
author’s name, year of publication, trial phase, the number of
patients evaluable, the number of arms, drugs used in the
experimental and in the control arm, dosage, rate of patients
with Eastern Cooperative Oncology Group Performance Status
(ECOG-PS) of 0, 1 or 2; and median overall survival (OS) with the
relative hazard ratio and 95% CI.
Statistical method
The HR for OS with the relative 95% CIs was extracted from
each study. Summary HR for OS was calculated using a
hierarchical Bayesian model [14], where logarithm of study HR
was assumed to be normally distributed [15], each study effect was
assumed to arise from a Gaussian centered on a study-specific log-
HR and the extracted standard error, inflated by 25% to obtain a
conservative statement. The study-specific log-HR was assumed to
be Gaussian, centered on a pooled log-HR, which is the main
object of interest. An informative prior is used for the variance of
the pooled HR, as an inverse Gamma centered on an estimator
obtained with a moment-based approach (inflated by 25% to
obtain a conservative statement). Indirect comparisons were
conducted by means of a similar model, assuming an additive
shift for the difference of effects on the log-HR scale.
A two-tailed p-value of less than 0.05 was considered statistically
significant. All data were collected using Microsoft Office Excel
2007; statistical analyses were performed using R software [16].
Results
The electronic search revealed 72 citations. After screening, 49
articles were eliminated because 23 were studies on adjuvant or
neoadjuvant therapy, 6 were surgical studies and 20 were related
to other aspects of gastric cancer. Among the remaining 23 studies
on patients with advanced disease, 18 were eliminated because
treatments were administered as first-line. At the end of the review
process, only five articles were included in the meta-analysis
because of their adequate quality and availability of data
(Figure 1) [11,17–20]. Among these, only four were considered
positive because reached the primary end-point [11,18–20]. The
characteristics of each study are presented in Table 1.
Overall population
A total of 1,424 patients were available for this trial-based meta-
analysis and among these 1,407 were evaluable for efficacy. The
majority of patients had an ECOG performance status of 0 or 1,
being the 95% and 83% in the experimental and control arm,
respectively. A total of 908 patients were treated in the
experimental arm, and among these 231 received chemotherapy
and 677 received targeted therapies. In the experimental arm, the
type of chemotherapy used was docetaxel (150 patients) or
irinotecan (81 patients), while the targeted therapies were the
anti-VEGFR-2 therapy ramucirumab (238 patients) or the
mammalian target of rapamycin inhibitor (mTORi) everolimus
(439 patients). In the control arm, patients were all treated with
BSC with or without placebo.
In the overall population, the active treatment decreases the risk
of death by 18% (HR=0.82; 95% CI 0.79–0.85; posterior
probability of HR$1: ,0.00001) (Table 2). When analysis was
limited to studies reaching the primary end point the reduction of
the risk of death was by 27% (HR=0.73; 95% CI 0.61–0.86;
posterior probability of HR$1: p,0.00001), as reported in
Table 2.
Survival by type of therapy
When populations were divided based on type of therapy
(chemotherapy vs. anti-VEGFR vs. mTORi), chemotherapy was
able to decrease the risk of death by 27% (HR=0.73; 95% CI,
0.58–0.96; posterior probability of HR$1: 0.00942). On the other
hand, treatment with ramucirumab was able to decrease the risk of
death by 22% (HR=0.78; 95% CI, 0.60–1.00), while no
significant effect on OS was seen with everolimus (HR=0.90;
95% CI, 0.75–1.08).
Survival by performance status
When populations were divided based on ECOG-PS, the 461
patients with ECOG 0 had a greater benefit when treated with
chemotherapy over BSC, with a reduction of the risk of death by
43% (HR=0.57; 95% CI, 0.36–0.91; posterior probability of
HR$1: 0.0092). In this group of patients, no benefit was found for
ramucirumab or everolimus over BSC; indirect comparison found
a better outcome for patients treated with chemotherapy
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compared to ramucirumab (posterior probability of chemotherapy
worse than or equivalent to ramucirumab: 0.00439) (Table 3).
In the 912 patients with ECOG-PS = 1 or more, a trend for
greater efficacy was confirmed for those treated with chemo-
therapy compared to patients treated with BSC, but difference
was not strong (HR= 0.80; 95% CI, 0.34–1.89; posterior
probability of HR$1: 0.07). In the same group of patients, a
significant effect was found for those treated with ramucirumab
over BSC with a reduction of the risk of death by 32%
(HR= 0.68; 95% CI, 0.51–0.92; p = 0.04) (Table 4). Indirect
comparison did not report differences between patients treated
with chemotherapy or ramucirumab (posterior probability of
chemotherapy worse than or equivalent to ramucirumab:
0.7622).
In summary, regardless of treatment, very little evidence was
found for efficacy in patients with ECOG-PS= 0 (HR=0.88; 95%
CI, 0.61–1.28; posterior probability of HR$1: 0.174), due to the
fact that ramucirumab and everolimus do not report a significant
decrease of the risk of death, while a benefit was found for
chemotherapy. On the other hand, a mild evidence of efficacy was
found for patients with PS= 1 or more, with a reduction of 21%
(HR=0.79; 95% CI, 0.64–0.98; posterior probability of HR$1:
0.015). Indirect comparison indicated that any active therapy over
BSC was more effective on patients with ECOG-PS= 1 or more
vs. ECOG-PS=0 (posterior probability of HR in ECOG=0
better than HR in ECOG=1: ,0.0001), suggesting that patients
with symptomatic disease should not be immediately excluded by
further lines of therapy.
Quality of the studies
Jadad’ scores for each trial are listed in Table 1; the mean score
was 3.2, confirming the good-quality of the included trials.
Discussion
First-line treatment of advanced GC with modern regimens
confers a benefit of OS exceeding ten months. Even if the addition
of trastuzumab to cisplatin-based chemotherapy significantly
improved OS in HER-2 positive GC [21], the outcome of the
majority of patients is still poor and disease progression invariably
occurs.
In metastatic phase, the role of second-line was largely debated
because the risk to expose patients to treatment toxicity is high due
to performance status deterioration and disease-related symptoms.
Up to date, this analysis is the largest to report that second-line
treatment is able to decrease the risk of death by 18%, with a more
evident effect in favor of chemotherapy reaching a risk reduction
of 27%. Despite the higher absolute benefit of chemotherapy, we
are unable to find a relative superiority of this strategy over the
targeted agent ramucirumab.
Studies included in this analysis reported that second-line
chemotherapy increased the median OS of about two months as
compared to BSC. In this context, the choice of the best drugs to
use according to efficacy, toxicity and individual patients
characteristics remain a open issue. A recent meta-analysis showed
that different drugs such as docetaxel or irinotecan, or different
administration schedules did not have any influence on outcomes
[22]. In facts, the objective response rate and the disease control
rate were similar and the decreased risks of death were 29% for
docetaxel (HR=0.71; 95% CI, 0.56–0.90) and 45% for irinotecan
(HR=0.55; 95% CI, 0.40–0.77) over BSC, respectively [22].
Despite this difference, a prospective phase III study comparing
weekly paclitaxel to irinotecan as second-line of therapy in GC
patients did not show significant differences. The results were a
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median OS of 8.4 and 9.5 months (HR 1.132; 95% CI, 0.86–1.49;
p = 0.38), a median PFS of 2.3 and 3.6 months (HR 1.14; 95% CI,
0.88–1.49; p = 0.33), and an ORR of 13.6% and 20.9% (p= 0.20)
for irinotecan and paclitaxel, respectively [23]. Another phase II
study that compared the a novel liposomal formulation of
irinotecan (PEP02) to standard irinotecan or docetaxel confirmed
Figure 1. Flowchart of search process.
doi:10.1371/journal.pone.0108940.g001
Table 2. Overall Survival in overall population and based on type of studies.
Type of study Trial Year N6 of Patients HR (95% CI)
Experim. Arm Control Arm
Positive studies Thuss-P. PC et al. 2011 21 19 0.48 (0.25–0.92)
Kang JH et al. 2012 133 69 0.66 (0.48–0.89)
Fuchs CS et al. 2014 238 117 0.78 (0.60–1.00)
Ford HER et al. 2014 84 84 0.67 (0.49–0.92)
Subtotal 476 289 0.73 (0.61–0.86)
Negative studies Ohtsu A et al. 2013 439 217 0.90 (0.75–1.08)
TOTAL 915 506 0.82 (0.79–0.85)
Second-Line Therapy in Gastric Cancer
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the lack of any significant advantage in favor of any therapy when
compared to other ones [24].
If the role of chemotherapy in second-line treatment of GC was
clearly demonstrated, the role of combination chemotherapy over
single agent remain an open issue. At least two studies tested this
hypothesis comparing two different regimens. The first one
compared the activity of irinotecan and 5-FU (FOLFIRI regimen)
over irinotecan alone, reporting no significant difference in term of
response rate (20.0 vs. 17.2%; p= 0.525), median PFS (3.0 vs. 2.2
months; p = 0.481) or OS (6.7 vs. 5.8 months; p = 0.514) [25]. The
second one comparing docetaxel +59DFUR to docetaxel alone,
reported a significant survival benefit for the combination (7.6 vs.
4.0; p,0.05) [26], increasing the confusion in this area. Probably,
new large phase III studies will be indispensable in order to better
understand the role of combination chemotherapy in the salvage
setting.
Until now, two evidence-based strategies are available for
patients after first-line of therapy: single agent chemotherapy or
targeted therapy such as ramucirumab. Even if the decreased risk
of death seems to be higher with the use of chemotherapy in
patients with ECOG-PS= 0 and for ramucirumab in patients with
ECOG-PS= 1 or more, considering the nature of this analysis, no
definitive conclusion may lead in favor of one strategy or the other,
while a prospective trial may better address to this fascinating
question.
It is noteworthy to mention the results of a recent placebo-
controlled, randomized phase III trial that compared weekly
paclitaxel and ramucirumab over weekly paclitaxel alone (RAIN-
BOW study). For the first time, in the second-line setting, the
addition of a targeted agent to standard chemotherapy demon-
strated a significant survival advantage increasing the median OS
from 7.36 to 9.63 months (p = 0.0169) and the median PFS from
2.9 to 4.4 months [27]. This positive outcome was reported both in
PS= 0 and PS=1 patients even if a statistical significant benefit
was reached only in the PS= 1 patients [27].
Both studies confirm such as the anti-VEGFR2 monoclonal
antibody seems to be more active compared to anti-VEGF ones or
to anti-VEGFR tyrosine kinase inhibitors. Unfortunately, the
reason for these differences is a current challenge and further
studies may elucidate the pharmacological differences and
probably to improve clinical outcome [28].
Considering the different toxicity profile – of any grade – we
account such as ramucirumab was mainly characterized by:
fatigue (36%), abdominal pain (29%), decrease of appetite (24%)
and vomiting (20%) and by hematological toxicities such as arterial
hypertension (16%) and bleeding or hemorrhage (13%) [11]. On
the other hand, docetaxel was characterized by the hematological
ones such as anemia (28%), neutropenia (16%) other than by
specific gastrointestinal (86%), dermatological (42%), or neurolog-
ical (30%) toxicities [18,20]. Moreover, the choice of irinotecan
seems not improve the toxicity profile of taxanes-based chemo-
therapy as reported by comparative studies [19,23,24].
Even if no definitive data are available about the best treatment
strategy for these patients, it is evident that patients’ clinical
conditions and co-morbidities, as well as the residual toxicities and
the magnitude of benefits from first-line treatment, may all have a
role in the choice of second-line therapy.
Table 3. Overall Survival by type of therapy in patients with ECOG performance status of 0.
Type of therapy Trial Year N6 of Patients HR (95% CI)
Experim. Arm Control Arm
Chemotherapy Kang JH et al. 2012 72 36 0.59 (0.38–0.90)
Ford HER et al. 2014 22 19 0.48 (0.24–0.95)
Subtotal 94 55 0.57 (0.36–0.91)
mTOR inhibitor Ohtsu A et al. 2013 144 70 1.14 (0.81–1.61)
VEGFR inhibitor Fuchs CS et al. 2014 67 31 1.07 (0.64–1.81)
TOTAL 305 156 0.88 (0.61–1.28)
Table 4. Overall Survival by type of therapy in patients with ECOG performance status of 1 or more.
Type of therapy Trial Year N6 of Patients HR (95% CI)
Experim. Arm Control Arm
Chemotherapy Kang JH et al. 2012 61 33 0.72 (0.46–1.13)
Ford HER et al. PS = 1 2014 45 50 0.80 (0.53–1.21)
Ford HER et al. PS = 2 2014 13 12 0.81 (0.36–1.82)
Subtotal 119 95 0.80 (0.34–1.89)
mTOR inhibitor Ohtsu A et al. PS = 1 2013 269 120 0.86 (0.58–1.08)
Ohtsu A et al. PS = 2 2013 25 27 1.43 (0.82–2.48)
Subtotal 294 147 0.92 (0.70–1.23)
VEGFR inhibitor Fuchs CS et al. 2014 171 86 0.68 (0.51–0.91)
TOTAL 584 328 0.79 (0.64–0.98)
Second-Line Therapy in Gastric Cancer
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In this study, we analyzed the activity of different type of
therapy in relationship with patient’ performance status at the start
of treatment and we found out that the benefit of chemotherapy
was more evident in asymptomatic patients with ECOG=0, with
a reduction of the risk of death by 43% (HR=0.57) as compared
to patients with symptomatic disease (HR=0.80). In this
population with suboptimal performance status, the benefit of
any type of therapy in terms of decreased risk of death is only by
21%, although it may be increased to 32% with the use of
ramucirumab. Probably, a good baseline clinical condition
increases the tolerability to chemotherapy and to its related
toxicity, on the other hand, the use of a less-toxic approach might
be preferred in patients with worse clinical conditions in order to
improve quality of life.
This analysis may be influenced by several factor such as the low
number of patients – less than 35% – with ECOG=0 compared
to patients with ECOG=1 or more in the included studies.
Nevertheless, some other limitations may affect these results.
First, and foremost, this is a trial-level meta-analysis based on
studies and not on individual patient data. Confounding variables
such as patient co-morbidities, extent of disease and differences in
other possible prognostic factors could not be incorporated into
such an analysis. Second, all the included studies were conducted
in selected patients with adequate organ function and no severe
co-morbidities at the time of study entry. Third, the data on the
correlation between ECOG PS and outcomes derived from
subgroup analyses of published studies.
Conclusions
Finally, this study confirms a significant benefit in terms of OS
when active second-line treatments are administered to patients
with advanced gastric cancer after failure of a previous line of
therapy even in patients with impaired performance status.
If the lack of difference between chemotherapy agents was
reported by other studies, we suggest a lack of difference between
chemotherapy and ramucirumab. Further studies are urgently
required to better understand the clinical or molecular character-
istic for patient’ selection.
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